Exosomes derived from human umbilical cord mesenchymal stem cells attenuate hepatic ischaemia-reperfusion injury via the let-7i-5p/Faslg axis

Figure 2 Human umbilical cord mesenchymal stem cell-derived exosomes attenuate apoptosis in LO2 cells following hypoxia/reoxygenation injury. A: Representative fluorescence images of LO2 cells in the hypoxia/reoxygenation and human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-exos) treatment groups showing the uptake of DiI-labelled exosomes. Scale bars: 25 μm; B: Representative light microscopy images of LO2 cells in the hypoxia/reoxygenation and hucMSC-exos treatment groups. Scale bars: 50 μm; C: TUNEL staining of LO2 cells. Scale bars: 50 μm; D: Flow cytometry analysis of apoptosis levels; E: Effects of hucMSC-exos on the protein levels of apoptosis-related markers in LO2 cells. H/R: Hypoxia/reoxygenation; hucMSC-exos: Human umbilical cord mesenchymal stem cell-derived exosomes; LFA-1: Lymphocyte function-associated antigen-1; VLA-4: Very late antigen-4; DiI: 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate; DAPI: 4’,6-diamidino-2-phenylindole; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling; Bax: B-cell lymphoma-2-associated X protein; Bcl-2: B-cell lymphoma-2; Caspase-3: Cysteinyl aspartate specific proteinase-3; OD: Optical density; 7-AAD: 7-aminoactinomycin D. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, and ^dP < 0.0001.